VOR vs. ANAB, ABVX, ZVRA, ALLO, SIGA, RNAC, PRTC, GLUE, KALV, and ESPR
Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include AnaptysBio (ANAB), ABIVAX Société Anonyme (ABVX), Zevra Therapeutics (ZVRA), Allogene Therapeutics (ALLO), SIGA Technologies (SIGA), Cartesian Therapeutics (RNAC), PureTech Health (PRTC), Monte Rosa Therapeutics (GLUE), KalVista Pharmaceuticals (KALV), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.
Vor Biopharma vs.
Vor Biopharma (NYSE:VOR) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.
97.3% of Vor Biopharma shares are held by institutional investors. 4.7% of Vor Biopharma shares are held by company insiders. Comparatively, 33.7% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Vor Biopharma has a beta of -0.51, meaning that its stock price is 151% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.
AnaptysBio received 315 more outperform votes than Vor Biopharma when rated by MarketBeat users. However, 69.33% of users gave Vor Biopharma an outperform vote while only 66.01% of users gave AnaptysBio an outperform vote.
In the previous week, Vor Biopharma had 2 more articles in the media than AnaptysBio. MarketBeat recorded 4 mentions for Vor Biopharma and 2 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.95 beat Vor Biopharma's score of 0.34 indicating that AnaptysBio is being referred to more favorably in the news media.
Vor Biopharma has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. Vor Biopharma's return on equity of 0.00% beat AnaptysBio's return on equity.
Vor Biopharma presently has a consensus target price of $11.36, suggesting a potential upside of 747.55%. AnaptysBio has a consensus target price of $41.45, suggesting a potential upside of 178.03%. Given Vor Biopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vor Biopharma is more favorable than AnaptysBio.
Vor Biopharma has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Vor Biopharma beats AnaptysBio on 10 of the 16 factors compared between the two stocks.
Get Vor Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vor Biopharma Competitors List
Related Companies and Tools
This page (NYSE:VOR) was last updated on 1/15/2025 by MarketBeat.com Staff
Free VOR Stock Alerts